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http:WHAT THIS PAPER ADDS
Current studies on endovascular therapy of thoracic aortic pathologies are characterized by a signiﬁcant het-
erogeneity of endpoints. This Trans-Atlantic multidisciplinary manuscript offers uniform reporting standards for
endovascular therapy of thoracic aortic pathologies and aims at improving study across outcomes across clinical
trials in the future.Objectives: Endovascular therapy is a rapidly expanding option for the treatment of patients with aortic
dissection (AD) and various studies have been published. These trials, however, are often difﬁcult to interpret and
compare because they do not utilize uniform clinical endpoint deﬁnitions.
Methods: The DEFINE Group is a collaborative effort of an ad hoc multidisciplinary team from various specialties
involved in AD therapy in Europe and the United States. DEFINE’s goal was to arrive at a broad based consensus
for baseline and endpoint deﬁnitions in trials for endovascular therapy of various vascular pathologies. In this
project, which started in December 2006, the individual team members reviewed the existing pertinent
literature. Following this, a series of telephone conferences and face-to-face meetings were held to agree upon
deﬁnitions. Input was also obtained from regulatory (United States Food and Drug Administration) and industry
(device manufacturers with an interest in peripheral endovascular revascularization) stakeholders, respectively.
Results: These efforts resulted in the present document containing proposed baseline and endpoint deﬁnitions
for clinical and morphological outcomes. Although the consensus has inevitably included certain arbitrary
consensus choices and compromises, adherence to these proposed standard deﬁnitions would provide
consistency across future trials, thereby facilitating evaluation of clinical effectiveness and safety of various
endovascular revascularization techniques.
Conclusions: This current document is based on a broad based consensus involving relevant stakeholders from
the medical community, industry and regulatory bodies. It is proposed that the consensus document may have
value for study design of future clinical trials in endovascular AD therapy as well as for regulatory purposes.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Endovascular therapy is a rapidly evolving option for the
treatment of patients with pathologies of the descending
aorta such as intramural hematoma, penetrating aortic ul-
cer (PAU), and aortic dissection (AD).1,2 The excitement
generated by the prospects of new technology has led
endovascular therapists of various specialty backgrounds to
pursue novel endovascular approaches for this life-
threatening vascular pathology.rresponding author. N. Diehm, Department of Clinical and Inter-
al Angiology, Berne University Hospital and University of Berne,
gstrasse, 3010 Bern, Switzerland.
il address: nicolas.diehm@insel.ch (N. Diehm).
-5884/$ e see front matter  2013 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2013.08.017Clinical trials are of utmost importance in the assessment
of new technologies to ascertain clinical efﬁcacy and safety,
thereby prompting adoption for clinical use following reg-
ulatory approval. Various clinical studies assessing endo-
vascular technologies have recently been published.
However, substantial variability in endpoint deﬁnitions has
created a signiﬁcant barrier for comparison of results across
these trials.3
In an attempt to remedy these issues, an assembly of
experts came together on an ad hoc basis to create uniform
deﬁnitions by which future research could be conducted.
The DEFINE Group was founded in 2006, consisting of a
broad interdisciplinary team (interventional angiologists,
cardiologists, and radiologists as well as vascular surgeons,
an endovascular neurosurgeon, and non-invasive vascular
medicine specialists) from Europe and the United States.
The mission of the DEFINE efforts was to create sets of
646 N. Diehm et al.deﬁnitions aimed at increasing consistency in future endo-
vascular therapy trials.4,5 The DEFINE group reviewed
scientiﬁcally sound, peer-reviewed literature and, after
extensive correspondence and meetings, proposed the
deﬁnitions outlined in the present manuscript. Two meet-
ings including all authors of the manuscript, along with
representatives of the United States Food and Drug
Administration (FDA) and commercial device manufacturers
were held in New York in November 2011 and in November
2012. Several teleconferences were required to continue
the consensus process. Given the multidisciplinary aspects
of the members of the DEFINE writing group, we strived for
a non-biased consensus that would be generally accepted
within future trials, regardless of specialty or nation.
Key components of this effort included deﬁnitions for
baseline clinical and anatomic characteristics,6 clinical out-
comes relevant to the patients, morphologic outcomes, and
complications. Existing standards were modiﬁed and
updated, if necessary, to apply speciﬁcally to endovascular
procedures and to reﬂect new insights that have emerged
over the last decade.
Given the contribution by the multidisciplinary scientiﬁc
members and by regulatory authorities, we hope that the
deﬁnitions described in the present manuscript will be
applicable for future clinical investigations.PROPOSED DEFINITIONS FOR ACUTE DESCENDING AORTIC
PATHOLOGIES
Aortic dissection
Acute aortic dissection is characterized by the rapid devel-
opment of an intimal ﬂap separating the true from the false
lumen.7e9 In the majority of cases, intimal tears are iden-
tiﬁed as sites of communication between true and false
lumen. The dissection can spread in an antegrade or
retrograde fashion, involving side branches and causing
complications such as malperfusion syndrome by dynamic
or static obstruction (from coronary to iliac arteries),
rupture, tamponade, or aortic insufﬁciency. From a patho-
physiological point of view, progression of dissection is
difﬁcult to predict once a patient with dissection has sur-
vived the initial 2 weeks after inception, although false
lumen expansion is likely to develop over time. Several
clinical features may be used to roughly estimate late risk,
including evidence of persistent communication, patent
false channel, and others.6,10Intramural hematoma
Aortic intramural hematoma is considered a precursor of
classic dissection, and originates from ruptured vasa vasorum
in medial wall layers, eventually provoking a secondary
communication with the aortic lumen.11e13 This process may
be initiated by ‘aortic wall infarction’. Bloodwithin themedial
wall space in the absence of an intimal tear is deﬁned as
intramural hematoma (IMH). It should be noted that the
inability to detect a small intimal defect (or fenestration) may
allow patients with true dissections to be classiﬁed as IMH,thus the assessment of the lumen, status of the ﬂuid in the
media, and proper imaging are critical. IMH may progress
into dissection if an intimal defect occurs either as a result of
rupture from the media through the intima or vice versa.
Similar to classic dissection, intramural hematoma may
extend along the aorta or progress, regress, or reabsorb.14 The
prevalence of intramural hematomas is 10e30% in patients
with acute aortic diseases and can lead to acute aortic
dissection in 21e47% of patients or to regression in about
10%.11,13,15,16 Involvement of the ascending aorta is consid-
ered an indication for expeditious surgery due to the inherent
risk of rupture, tamponade, or compression of coronary artery
ostia. Distal intramural hematoma may warrant watchful
waiting and, potentially, stent-graft placement in case of local
expansion.13,16e18 Thus, IMHs of the ascending aorta should
be reported separately from distal IMHs.
Penetrating aortic ulcer
Ulceration of atherosclerotic aortic plaques can lead to
aortic dissection or perforation.14,19e21 Non-invasive imag-
ing of aortic ulceration has been improved by tomographic
scanning and has shed light on pathophysiology and etiol-
ogy. Aortic ulcers occur predominantly in the descending
thoracic and abdominal aorta, penetrate intimal borders,
and appear in nipple-like projections with an adjacent he-
matoma;22,23 symptomatic ulcers and/or with signs of deep
erosion are more likely to rupture than others.
Natural history
Acute aortic dissection of the descending aorta is less
frequently lethal than that of the ascending aorta. In the
absence of treatment, survival rates are 89% at 1 month,
84% at 1 year, and 80% at 5 years.24 However, patients with
complications such as renal failure, visceral ischemia, or
contained rupture often require urgent repair, with a mor-
tality of 20% at day 2 and 25% at 1 month. Advanced age,
rupture, shock, and malperfusion are important indepen-
dent predictors of early mortality.24
The observation that older age (>55 years) at initial diag-
nosis of IMH has a better long-term prognosis may be
explained by more focal microscars along the aortic wall
inherently limiting the longitudinal progression of IMH.24
Accordingly, favorable outcomes of IMH are consistently re-
ported in patients beyond 65 years.24 Thus, considering both
advanced aortosclerosis with older age and the lower risk of
progression, a conservative strategy (with b-blockade and
serial imaging) appears to be justiﬁed in elderly medically frail
patients and in distal IMH.24 Ulcer-like projections in aortic
segments of IMH identify a subset of patients at high risk.
Aortic ulcers are preferentially (>90%) observed in IMH of the
descending aorta, while IMH without PAU is more frequently
present in the ascending aorta. Symptomatic PAU incurs
complications such as formation of aneurysm, pseudoaneur-
ysm, and dissection, or unpredictable rupture. Careful imaging
is vital to identify both diameter and depth of ulcers with IMH,
since width>2 cm and depth>1 cmmay herald the need for
interventional or surgical repair to avoid rupture and death.25
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Endpoint deﬁnitions encompass immediate procedural
success, complications, and clinical outcome during follow-
up.4,5 All failures occurring within 30 days of the procedure
(i.e. absence of procedural success) are considered “acute
procedural failures”, and are attributed to the procedure. To
evaluate clinical outcomes we propose a minimum follow-
up period of 12 months, which is considered short-term
follow-up. Mid-term follow-up refers to follow-up periods of
greater than 1e3 years and long-term follow-up to be
greater than 3 years of post-procedural follow-up. Clinical
follow-up pertains to any information regarding the clinical
status of the patient including mortality.
Mortality
Patient mortality after enrolment in a study must be
assessed during follow-up. Aneurysm/dissection-related
mortality has to be differentiated from all-cause mortality.
Causes of death associated with the endovascular proce-
dure (procedure-related mortality, i.e. mortality within 30
days post procedure or mortality during a hospitalization
>30 days due to the procedure) should be reported sepa-
rately as well as overall mortality.
Freedom from reintervention
Freedom from open surgical and endovascular reinterven-
tion should be reported separately.
Neurological sequelae
 Stroke
 Spinal cord ischemia/paresis-paralysis
 Vertebral insufﬁciencyIschemic symptoms
Visceral ischemia. Symptoms requiring surgical or endo-
vascular intervention versus symptoms not requiring inter-
vention should be differentiated at baseline and follow-up.
Renal ischemia/renal dysfunction. Symptoms requiring
surgical or endovascular intervention versus symptoms not
requiring intervention should be differentiated at baseline
and follow-up. Need for dialysis (temporary vs. chronic)
should be reported.
Lower extremity ischemia. Symptoms requiring surgical or
endovascular intervention versus symptoms not requiring
intervention should be differentiated at baseline and follow-
up.
Upper extremity ischemia.
 Intermittent dyspraxia of the left arm at baseline and
follow-up
 Subclavian steal syndromeSymptoms requiring surgical or endovascular interven-
tion versus symptoms not requiring intervention should be
differentiated at baseline and follow-up.
Morphological outcomes
Contrast-enhanced computed tomography angiography re-
mains the gold standard for imaging of thoracic aortic pa-
thologies post endovascular treatment.26 The following
parameters should be reported:
Aortic diameters6.
 Maximum transverse aortic diameter measured
perpendicular to the aortic centerline, baseline versus
follow-up
 Minimal diameter of the true lumen and maximal
diameter of the false lumen
 Increase/decrease of maximum transverse diameter
>5 mm
 Stable transverse diameter <5 mm change
 Increase of diameter to >6 cm
 Rupture
 PerforationMembrane rupture. Segmental extent of aortic involve-
ment from proximal to distal boundary according to
DISSECT deﬁnitions.6
Progression of dissection (perioperatively and follow-up
vs. baseline):6
 antegrade: progression distally from the primary entry
tear
 retrograde: progression distally from the primary entry
tear.Status of false lumen6.
 Patent, deﬁned as evidence of ﬂow or contrast
opaciﬁcation within the false lumen throughout the
length of the dissected aorta
 Partially patent/thrombosed, deﬁned as longitudinal
thrombosis of a portion of the aortic false lumen or
circumferential thrombus that partially ﬁlls the false lumen
 Thrombosed, deﬁned as absence of ﬂow or contrast
opaciﬁcation within the initially visualized false lumen
on contrast-enhanced computed tomography scanStatus of endovascular device
 Type 1 and 3 Endoleak as deﬁned elsewhere27
 Graft migration deﬁned as movement of >10 mm
relative to anatomic landmark with the use of three-
dimensional computed tomography reconstruction using
a centerline of ﬂow or any migration leading to
symptoms or requiring intervention27
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using a standardized protocol with anteroposterior and
lateral projections27
 Graft infolding deﬁned as the lack of apposition of the
proximal stent-graft to the aortic wall, with a wedge-
shapedgapbetweentheundersurfaceof thestent-graftand
the aorticwall along the lesser curvatureof the aortic arch28
 Graft collapse deﬁned as aortic occlusion resulting from
graft infoldingProcedural success
Technical or device success is deﬁned as successful introduc-
tion and deployment of the device at the intended segment
with successful coverage of the primary tear site deﬁned as
the proximal margin of the origin of the dissection.6
Procedural success is deﬁned as the composite of tech-
nical success, absence of the need for conversion to open
surgery or immediate endovascular reintervention, absence
of aortic death, absence of graft thrombosis, obstruction,
twisting or kinking or graft migration >10 mm proximally or
distally, absence of failure of graft integrity, absence of
aneurysm rupture and absence of increase in aortic diam-
eter >5 cm within 30 days of the baseline procedure.
Hemodynamic outcome
Hemodynamic stabilization deﬁned as absence of need for
mechanical or drug support to maintain circulation.
Complications
Complications should be reported according to the general
clinical research guidelines and the applicable (local) laws.
For the purpose of this guidance document on deﬁnitions
for complications, reference is made to the International
Society for Standardization (ISO) 14155, the International
Conference on HarmonisationeGood Clinical Practice (ICH-
GCP) guidelines and the Food and Drug Administration
(FDA) 21 Code of Federal Regulations (CFR) chapter x812.3.
The primary mode of action of the investigational prod-
uct as well as the region where the trial is performed will
determine which regulations must be used. Additionally,
combined products or non-medical devices may require
using a combination of these guidelines.
Any untoward occurrence in a subject should be differ-
entiated as follows:
 Adverse events (AE)
 Serious adverse events (SAE)
 Adverse device effect
 (Serious) Adverse device effect (SADE)
 Unanticipated adverse device effect (UADE)
 Major adverse event (MAE)
In case the investigational product is classiﬁed different
than a medical device, other general deﬁnitions may be
applicable (e.g. Suspected Unexpected Serious Adverse
Reaction [SUSAR]).Adverse events (AE) e ISO 14155 (3.2)
Any untoward medical occurrence, unintended disease or
injury, or untoward clinical signs (including abnormal labo-
ratory ﬁndings) in subjects, users or other persons, whether
or not related to the investigational medical device.NOTE 1: This deﬁnition includes events related to the
investigational medical device or the comparator.
NOTE 2: This deﬁnition includes events related to the
procedures involved.
NOTE 3: For users or other persons, this deﬁnition is
restricted to events related to investigational medical
devices.Serious adverse event (SAE) e ISO 14155 (3.37)
A SAE is an AE that
 led to a death
 led to a serious deterioration in the health of the subject
that resulted in
e a life-threatening illness or injury
e permanent impairment of a body structure or a body
function
e inpatient hospitalization or prolongation of existing
hospitalization
e medical or surgical intervention to prevent permanent
impairment to body structure or a body function
 led to fetal distress, fetal death or a congenital
abnormality or birth defect.NOTE: Planned hospitalization for a pre-existing
condition, or a procedure required by the CIP, without
serious deterioration in health, is not considered a
serious adverse event.All AEs, whether serious or not, must be rated “related or
unrelated” to the investigational product.Adverse device effect e ISO 14155 (3.1)
An adverse device defect is deﬁned as any untoward and
unintended response to a medical device.NOTE 1: This deﬁnition includes adverse events
resulting from insufﬁcient or inadequate instructions
for use, deployment, implantation, installation, or
operation, or any malfunction of the investigational
medical device.
NOTE 2: This deﬁnition includes any event resulting
from use error or from intentional misuse of the
investigational medical device.Serious adverse device effect e ISO 14155 (3.36)
An adverse device effect that has resulted in any of the
consequences characteristic of a serious adverse event.
European Journal of Vascular and Endovascular Surgery Volume 46 Issue 6 p. 645e650 December/2013 649Unanticipated adverse device effecte FDA 21 CRF x812.3 (s)
Any serious adverse effect on health or safety or any life-
threatening problem or any life-threatening problem or
death caused by, or associated with, a device if that effect,
problem, or death was not previously identiﬁed in nature,
severity, or degree of incidence in the investigational plan or
application (including a supplementary plan or application),
or any other unanticipated serious problem associated with a
device that relates to the rights, safety or welfare of subjects
is deﬁned as an unanticipated adverse device effect.
Major adverse event
The MAE deﬁnition is different for each protocol and must
be deﬁned in the protocol.
It is recommended to use an independent committee
(Clinical Event or Data Safety and Monitoring Committee)
for the adjudication of the SAEs to determine if an event is a
MAE or not. The CEC may deﬁne, prior to the start of the
study, the type of events that will be reviewed and
adjudicated.
All AEs and SAEs must appear in the ﬁnal report. Infor-
mation related to the adjudication of the events may be
added. Reporting by the manufacturer/sponsor to the reg-
ulatory bodies must be performed according the speciﬁed
national regulations.
Additionally, the following occurrences should appear in
the related publication or at a minimum in the ﬁnal trial
report:
 procedural-related serious adverse events
 investigational product related serious adverse events
 device failure or malfunction.
Next to the MAE, the reported (serious) adverse events
should be classiﬁed and reported according to the following
four complication categories: access site complications,
vessel speciﬁc complications (treatment site including
proximal and distal to the site), organ-speciﬁc complica-
tions, systemic complications.
CONCLUSIONS
Endovascular treatment of descending aortic dissection is a
rapidly growing ﬁeld that has resulted in a number of
clinical trials. These differ across a heterogeneous com-
posite of deﬁnitions thereby resulting in reporting in-
consistencies and a lack of comparability across various
trials.
The present manuscript aimed to establish deﬁnitions as
a point of reference for future clinical trials.4,5 Use of the
latter will improve comparability of studies dealing with
endovascular therapy of AD to further elucidate and prove
long-term credibility of this method. Thus, adherence to
these deﬁnitions is recommended for future publications.
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